Source: Annual Congress 2002 - Thoracic oncology: biology
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. H. Lee, J. H. Chang (Seoul, South Korea). Alteration of p53 and FHIT genes in pleural effusion associated with malignancy. Eur Respir J 2002; 20: Suppl. 38, 138

Member's Comments

No comment yet.

Related content which might interest you: Diagnostic value of detection of promoter hypermethylation of tumor suppressor genes in pleural fluid for diagnosis of malignant pleural effusion Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010 Malignant pleural effusion cells show aberrant glucose metabolism gene expression Source: Eur Respir J 2011; 37: 1453-1465 Year: 2011 Prognostic value of promoter hypermethylation of tumor suppressor genes in malignant pleural fluid Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011 Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004 Timp-2 expression in the cytologic evaluation of adenocarcinoma pleural effusions Source: Annual Congress 2007 - Pleural malignancy Year: 2007 The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Comparison of telomerase activity in malignant and benign pleural effusions Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Diagnostic implications of telomerase activity in pleural effusions Source: Eur Respir J 2003; 22: 422-426 Year: 2003 Neurotrophin protein expression in pleural effusions Source: Annual Congress 2009 - Diagnosis and management of pleural effusions and mesothelioma: improving old techniques and new tools Year: 2009 Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 Evaluation of concomitant pleural effusions in patients with lung cancers Source: Eur Respir J 2007; 30: Suppl. 51, 668s Year: 2007 Different prevalence of positivity for human mammaglobin (hMAM) transcipts in the pleural fluid of patients with malignant vs. non malignant pleural disease Source: Eur Respir J 2006; 28: Suppl. 50, 580s Year: 2006 Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 The value of IL6 in differentiation between malignant and non malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Utility of LDH-A in the differentiation between lymphocytic pleural effusions of malignantand non-malignant etiology Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 The expression of PD-1 on CD8+ T cells in malignant pleural effusion of lung cancer and its associated significance Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Diagnostic and prognostic significance of survivin levels in malignant pleural effusion Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011 Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Source: Eur Respir J 2008; 32: 924-930 Year: 2008